After the outbreak of new coronary pneumonia, how to quickly and accurately screen and diagnose patients with new coronary pneumonia has become the top priority of epidemic prevention and control. In the context of the rapid development of various new technologies and the catalysis of the new crown pneumonia epidemic, the in vitro diagnostic (IVD) industry will develop rapidly and is expected to become one of the most active and fastest-growing markets in the medical device industry in the future.
New technologies, new models and new demands open up new spaces
With the rapid development of biotechnology, the market size of the global in vitro diagnostic industry is showing a rapid growth trend. According to data from the China In Vitro Diagnostic Network (CAIVD), in 2013, the global market size of the in vitro diagnostic industry was about 60 billion U.S. dollars, and it exceeded 80 billion U.S. dollars in 2019, with an average annual compound growth rate of 6%. It is expected that the market size is expected to exceed 900 in 2020. One hundred million U.S. dollars.
There are many subdivisions in the in vitro diagnostic industry, which can be divided into six areas: immunodiagnosis, biochemical diagnosis, blood diagnosis, molecular diagnosis, microbiological diagnosis and point-in-time diagnosis (POCT) based on detection principles and methods. From the perspective of the development trend of the global in vitro diagnostic market, in recent years, the market share of clinical biochemical diagnostics and immunodiagnostic products has decreased slightly, while the market share of nucleic acid identification, microbiology, histology and flow cytometry has increased year by year. , The average annual compound growth rate exceeds 10%. In 2019, among the various segments of the global in vitro diagnostics market, the immunodiagnostic market had the largest market share, accounting for 23%; followed by the biochemical diagnostics market, accounting for 17%.